SEC Filing Analysis: NEUROCRINE BIOSCIENCES INC (NBIX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director has filed a notice of a proposed sale of common stock valued at approximately $2.6 million, executed under a pre-established 10b5-1 trading plan.
• Market Impact: The transaction is immaterial relative to the company's market capitalization and public float, suggesting a neutral market impact.

Company Information

Field	Value
Company	NEUROCRINE BIOSCIENCES INC
Ticker Symbol	NBIX
CIK	0000914475
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	RASTETTER WILLIAM H
CIK	0001205903
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	144 (Notice of Proposed Sale)
Transaction Date	2025-11-05 (Approximate Sale Date)
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	18,000
Price Per Share	~$143.19 (implied)
Total Value	$2,577,420
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$2,577,420
% of Market Cap	0.018%
Shares Transacted	18,000
% of Shares Outstanding	0.018%
Post-Transaction Ownership	Not Disclosed
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $2.6 million sale is negligible for a company with a market capitalization of $14.28 billion.
• Transaction Significance: The sale represents a tiny fraction (0.018%) of the total shares outstanding, indicating it will have no dilutive effect or meaningful impact on the stock's public float. Such a small transaction is considered routine.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction's low value relative to market cap and its execution under a 10b5-1 plan (adopted 08/06/2025) signal that this is a planned liquidity event for the insider, not a reaction to non-public information.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction size is unlikely to cause any noticeable deviation from average trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by directors are common and typically do not influence market sentiment.

Additional Context

Special Circumstances

• The filing indicates the proposed sale is pursuant to a 10b5-1 trading plan adopted on August 6, 2025. This plan allows insiders to sell a predetermined number of shares at a predetermined time, providing an affirmative defense against accusations of trading on inside information.